JP2015518493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518493A5 JP2015518493A5 JP2015511471A JP2015511471A JP2015518493A5 JP 2015518493 A5 JP2015518493 A5 JP 2015518493A5 JP 2015511471 A JP2015511471 A JP 2015511471A JP 2015511471 A JP2015511471 A JP 2015511471A JP 2015518493 A5 JP2015518493 A5 JP 2015518493A5
- Authority
- JP
- Japan
- Prior art keywords
- bone
- cells
- subject
- composition
- stimulant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 239000003623 enhancer Substances 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 5
- 230000037361 pathway Effects 0.000 claims 5
- 210000001789 adipocyte Anatomy 0.000 claims 4
- 239000000090 biomarker Substances 0.000 claims 4
- 210000000988 bone and bone Anatomy 0.000 claims 4
- 230000004069 differentiation Effects 0.000 claims 4
- 239000007943 implant Substances 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 241000027355 Ferocactus setispinus Species 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- 230000011164 ossification Effects 0.000 claims 3
- 230000004072 osteoblast differentiation Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 241000289669 Erinaceus europaeus Species 0.000 claims 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 230000008468 bone growth Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000411 inducer Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000001582 osteoblastic effect Effects 0.000 claims 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 claims 1
- 229940122280 Cytochrome P450 inhibitor Drugs 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 claims 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims 1
- 101001023988 Homo sapiens Growth/differentiation factor 5 Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 102000004067 Osteocalcin Human genes 0.000 claims 1
- 108090000573 Osteocalcin Proteins 0.000 claims 1
- 102000003982 Parathyroid hormone Human genes 0.000 claims 1
- 108090000445 Parathyroid hormone Proteins 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 206010048214 Xanthoma Diseases 0.000 claims 1
- 206010048215 Xanthomatosis Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims 1
- 230000034127 bone morphogenesis Effects 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 230000003185 calcium uptake Effects 0.000 claims 1
- 230000002648 chondrogenic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000003779 hair growth Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000000921 morphogenic effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000002188 osteogenic effect Effects 0.000 claims 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 claims 1
- 239000000199 parathyroid hormone Substances 0.000 claims 1
- 229960001319 parathyroid hormone Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 235000013024 sodium fluoride Nutrition 0.000 claims 1
- 239000011775 sodium fluoride Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261643746P | 2012-05-07 | 2012-05-07 | |
| US61/643,746 | 2012-05-07 | ||
| PCT/US2013/032693 WO2013169399A1 (en) | 2012-05-07 | 2013-03-15 | Oxysterol analogue oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518493A JP2015518493A (ja) | 2015-07-02 |
| JP2015518493A5 true JP2015518493A5 (enExample) | 2016-07-28 |
| JP6262723B2 JP6262723B2 (ja) | 2018-01-17 |
Family
ID=49551140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511471A Active JP6262723B2 (ja) | 2012-05-07 | 2013-03-15 | オキシステロールアナログｏｘｙ１３３は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9717742B2 (enExample) |
| EP (1) | EP2847206A4 (enExample) |
| JP (1) | JP6262723B2 (enExample) |
| KR (1) | KR20150013232A (enExample) |
| CN (1) | CN104395331B (enExample) |
| AU (1) | AU2013260059B2 (enExample) |
| CA (1) | CA2872751A1 (enExample) |
| IN (1) | IN2014DN09805A (enExample) |
| RU (1) | RU2632191C2 (enExample) |
| WO (1) | WO2013169399A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005020928A2 (en) | 2003-08-29 | 2005-03-10 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
| CA2643732C (en) | 2006-02-27 | 2012-08-21 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| CA2707663C (en) | 2007-12-03 | 2017-05-30 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
| JP6262723B2 (ja) | 2012-05-07 | 2018-01-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | オキシステロールアナログｏｘｙ１３３は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する |
| AU2014259672A1 (en) | 2013-05-02 | 2015-12-03 | The Regents Of The University Of California | Bone-selective osteogenic oxysterol-bone targeting agents |
| JP6530056B2 (ja) * | 2014-05-02 | 2019-06-12 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア | 骨選択的骨形成オキシステロールビスホスホネート類似体 |
| CN107427526B (zh) | 2014-12-09 | 2021-08-03 | 华沙整形外科股份有限公司 | 涉及甾醇的化合物和方法 |
| WO2016187394A1 (en) * | 2015-05-19 | 2016-11-24 | Van Wijnen Andre J | Methods and materials for promoting bone formation |
| US9877836B2 (en) * | 2015-07-10 | 2018-01-30 | Warsaw Orthopedic, Inc. | Compression resistant implants including an oxysterol and methods of use |
| KR20180019646A (ko) * | 2015-06-17 | 2018-02-26 | 워쏘우 오르쏘페딕 인코포레이티드 | 옥시스테롤을 포함하는 임플란트 및 사용 방법 |
| US9987289B2 (en) * | 2015-07-10 | 2018-06-05 | Warsaw Orthopedic, Inc. | Slow release oxysterols and methods of use |
| US10632230B2 (en) * | 2015-07-10 | 2020-04-28 | Warsaw Orthopedic, Inc. | Implants having a high drug load of an oxysterol and methods of use |
| US9878070B2 (en) * | 2015-06-17 | 2018-01-30 | Warsaw Orthopedic, Inc. | Malleable implants including an oxysterol and methods of use |
| US12171909B2 (en) | 2015-07-10 | 2024-12-24 | Warsaw Orthopedic, Inc. | Implants having a drug load of an oxysterol and methods of use |
| US9637514B1 (en) | 2015-10-26 | 2017-05-02 | MAX BioPharma, Inc. | Oxysterols and hedgehog signaling |
| AU2016347052B2 (en) * | 2015-10-27 | 2021-03-25 | Warsaw Orthopedic, Inc. | Implants having a drug load of an oxysterol and methods of use |
| US11090411B2 (en) | 2016-01-28 | 2021-08-17 | Warsaw Orthopedic, Inc. | Electron beam irradiated osteoinductive bone implant |
| US20170275330A1 (en) * | 2016-03-28 | 2017-09-28 | Warsaw Orthopedic, Inc. | Polymorphic forms of an oxysterol and methods of making them |
| US9987290B2 (en) | 2016-03-28 | 2018-06-05 | Warsaw Orthopedic, Inc. | Methods for the separation and detection of an oxysterol |
| CN105924493A (zh) * | 2016-04-23 | 2016-09-07 | 何华琼 | 盐酸布桂嗪的药物组合物及其在生物医药中的应用 |
| US10688222B2 (en) * | 2016-11-21 | 2020-06-23 | Warsaw Orthopedic, Inc. | Lyophilized moldable implants containing an oxysterol |
| US11384114B2 (en) * | 2016-12-09 | 2022-07-12 | Warsaw Orthopedic, Inc. | Polymorphic forms of an oxysterol and methods of making them |
| US10294264B2 (en) | 2017-04-21 | 2019-05-21 | Warsaw Orthopedic, Inc. | Oxysterol-therapeutic agent derivative for bone healing |
| US10434106B2 (en) | 2017-05-19 | 2019-10-08 | Warsaw Orthopedic, Inc. | Oxysterol-statin compounds for bone growth |
| US11464888B2 (en) * | 2017-06-12 | 2022-10-11 | Warsaw Orthopedic, Inc. | Moldable formulations containing an oxysterol in an acellular tissue matrix |
| WO2019048898A1 (en) | 2017-09-05 | 2019-03-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION |
| KR102283508B1 (ko) * | 2020-04-17 | 2021-07-29 | 가톨릭대학교 산학협력단 | 골형성 단백질-2를 유효성분으로 포함하는 줄기세포 스페로이드의 골분화 촉진용 조성물 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB869007A (en) | 1956-10-03 | 1961-05-25 | Ciba Ltd | New heterocyclically substituted steroids |
| CH433275A (de) | 1963-07-09 | 1967-04-15 | Hoffmann La Roche | Verfahren zur Herstellung von 19-Alkylsteroiden |
| JPS5111114B1 (enExample) | 1969-03-14 | 1976-04-08 | ||
| US3887545A (en) | 1973-11-12 | 1975-06-03 | Hoffmann La Roche | Synthesis of 1{60 -hydroxylated cholesterol derivatives |
| US4264512A (en) | 1975-09-29 | 1981-04-28 | The Regents Of The University Of California | 3-Deoxy-1α-hydroxy- and 3-deoxy-1α,25-dihydroxycholecalciferol and processes for the preparation thereof |
| US4183852A (en) | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| US4743597A (en) | 1986-01-27 | 1988-05-10 | Javitt Norman B | Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| LU87201A1 (fr) | 1988-04-14 | 1989-11-14 | Cird | Complexes a base d'anthraline et d'un sterol,leur procede d'obtention et leur utilisation en therapeutique et cosmetique |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| EP0487587A1 (en) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| US5183815A (en) | 1991-01-22 | 1993-02-02 | Merck & Co., Inc. | Bone acting agents |
| GB9118465D0 (en) | 1991-08-29 | 1991-10-16 | Imperial College | Steroid sulphatase inhibitors |
| US5203975A (en) | 1991-10-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Process for cathodic electrodeposition of a clear coating over a conductive paint layer |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| DE69433592T2 (de) | 1993-11-09 | 2005-02-10 | Targeted Genetics Corp., Seattle | Die erzielung hoher titer des rekombinanten aav-vektors |
| US7060450B1 (en) | 1993-12-30 | 2006-06-13 | President And Fellows Of Harvard College | Screening assays for agonists and antagonists of the hedgehog signaling pathway |
| KR970700199A (ko) | 1994-01-06 | 1997-01-08 | 에드워드 이. 데이비스 | 신규한 항남성호르몬제 및 이와 관련된 조성물 및 사용방법(novel antiandrogenic agents and related pharmaceutical compositions and methods of use) |
| JP2000511404A (ja) | 1996-04-09 | 2000-09-05 | ビー・テイー・ジー・インターナシヨナル・リミテツド | 神経精神、免疫又は内分泌障害を治療するための７α置換ステロイドの使用 |
| CA2251983C (en) | 1996-04-19 | 2003-12-16 | Sudhakar Kadiyala | Regeneration and augmentation of bone using mesenchymal stem cells |
| US6893830B1 (en) | 1996-09-27 | 2005-05-17 | The Board Of Regents Of The University Of Texas System | Method of screening oxysterol activation of LXRα |
| US5840752A (en) | 1996-11-21 | 1998-11-24 | Henry; James P. | Reduction of hair growth |
| US5855920A (en) | 1996-12-13 | 1999-01-05 | Chein; Edmund Y. M. | Total hormone replacement therapy |
| US6080779A (en) | 1996-12-13 | 2000-06-27 | Osteoscreen, Inc. | Compositions and methods for stimulating bone growth |
| PL334840A1 (en) | 1997-01-24 | 2000-03-27 | Univ California | Application of fxr, pparalpha and lxralpha activators in order to restore the barrier function, to stimulate epithelium differentation and to inhibit proliferation |
| TR199902793T2 (xx) | 1997-05-16 | 2000-06-21 | Akzo Nobel N.V. | 20-Aralkil-5alfa-pregnan t�revleri. |
| DE19723794A1 (de) | 1997-06-06 | 1998-12-10 | Jenapharm Gmbh | Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität |
| US5929062A (en) | 1997-06-19 | 1999-07-27 | University Of Western Ontario | Oxysterol inhibition of dietary cholesterol uptake |
| WO1999000117A2 (en) | 1997-06-27 | 1999-01-07 | Ontogeny, Inc. | Neuroprotective methods and reagents |
| US20030153541A1 (en) | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
| AU2901199A (en) | 1998-03-13 | 1999-09-27 | Merck & Co., Inc. | Methods of inhibiting bone resorption |
| EP0943332A1 (en) | 1998-03-19 | 1999-09-22 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Prevention and treatment of adhesions |
| US6906069B1 (en) | 1999-01-08 | 2005-06-14 | Amgen Inc. | LXR modulators |
| ES2188515T3 (es) | 1999-03-09 | 2003-07-01 | Akzo Nobel Nv | Derivados de 22r-hidroxicolesta-8,14-dieno con actividad inhibidora de la meiosis. |
| US6316503B1 (en) | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
| US6586189B2 (en) | 1999-06-18 | 2003-07-01 | City Of Hope | Screening method for PPAR-γ ligands |
| AU1291901A (en) | 1999-09-01 | 2001-03-26 | University Of British Columbia, The | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| US20020115695A1 (en) | 2000-11-07 | 2002-08-22 | Paralkar Vishwas M. | Combination therapies for the stimulation of bone growth |
| GB0101933D0 (en) | 2001-01-25 | 2001-03-07 | Astrazeneca Ab | Therapy |
| WO2002080244A2 (en) | 2001-02-12 | 2002-10-10 | Asm America, Inc. | Improved process for deposition of semiconductor films |
| EP1401469A2 (en) | 2001-04-09 | 2004-03-31 | Lorantis Limited | Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| CN100430062C (zh) | 2002-03-15 | 2008-11-05 | 萨马里坦药品公司 | 神经保护性螺甾烯醇药用组合物 |
| EP1556057A4 (en) | 2002-08-29 | 2009-07-15 | Univ California | MEDIUM AND METHOD FOR REINFORCING BONE TRAINING |
| DE10307104A1 (de) | 2003-02-19 | 2004-09-23 | Schering Ag | Antitumor wirksame 2-substituierte Estra-1,3,5(10)-trien-3-yl sulfamate |
| NZ545087A (en) | 2003-07-09 | 2009-10-30 | Forbes Medi Tech Inc | Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions |
| WO2005028616A2 (en) | 2003-07-24 | 2005-03-31 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Morphogen compositions and methods of use thereof to treat heart disorders |
| AU2004267067A1 (en) | 2003-08-18 | 2005-03-03 | Wyeth | Human LXR alpha variants |
| WO2005020928A2 (en) | 2003-08-29 | 2005-03-10 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
| WO2005065315A2 (en) | 2003-12-24 | 2005-07-21 | University Of Louisville Research Foundation | Bone targeting compounds for delivering agents to the bone for interaction therewith |
| EP1758919A1 (en) | 2004-06-10 | 2007-03-07 | Merck & Co., Inc. | Estrogen receptor modulators |
| WO2006012902A2 (en) | 2004-08-02 | 2006-02-09 | Novozymes A/S | Creation of diversity in polypeptides |
| DE102004042822A1 (de) | 2004-08-31 | 2006-03-16 | Technische Universität Dresden | Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen |
| WO2006110490A2 (en) | 2005-04-07 | 2006-10-19 | The Regents Of The University Of California | Agents and methods for osteogenic oxysterols inhibition of oxidative stress on osteogenic cellular differentiation |
| EP1931353A4 (en) | 2005-09-02 | 2009-07-29 | Univ California | OSTEOGENIC AND ANTI-ADIOGENIC OXYSTEROLS |
| CA2643732C (en) | 2006-02-27 | 2012-08-21 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| US20100048944A1 (en) | 2006-07-19 | 2010-02-25 | Farhad Parhami | Interactions of hedgehog and liver x receptor signaling pathways |
| US20080070883A1 (en) | 2006-09-19 | 2008-03-20 | Wyeth | Use of LXR modulators for the prevention and treatment of skin aging |
| GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| WO2008082520A2 (en) | 2006-12-19 | 2008-07-10 | The Regents Of The University Of California | Inhibition of ppar gamma expression by specific osteogenic oxysterols |
| JP2010521423A (ja) | 2007-02-23 | 2010-06-24 | ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション，インコーポレーテッド | 骨と相互作用するために、骨へ作用剤を標的輸送するための方法および化合物 |
| WO2008109780A1 (en) | 2007-03-06 | 2008-09-12 | University Of Louisville Research Foundation, Inc | Methods and compounds for the targeted delivery of agents to bone for interaction therewith |
| WO2008115469A2 (en) | 2007-03-16 | 2008-09-25 | The Regents Of The University Of California | Role of hedgehog signaling in atherosclerosis and cardiovascular disease |
| CA2707663C (en) * | 2007-12-03 | 2017-05-30 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
| MY163799A (en) | 2008-02-07 | 2017-10-24 | Dsg Tech Holdings Limited | Method of making an absorbent composite and absorbent articles employing the same |
| WO2011006087A1 (en) | 2009-07-10 | 2011-01-13 | The Regents Of The University Of California | Inhibition of ppar gamma expression in preadipocyte cells by oxysterols |
| US20120309730A1 (en) | 2010-02-16 | 2012-12-06 | The Johns Hopkins University | Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling |
| WO2012024584A2 (en) * | 2010-08-20 | 2012-02-23 | Fate Therapeutics, Inc. | Oxysterol compounds |
| WO2012024583A2 (en) * | 2010-08-20 | 2012-02-23 | Fate Therapeutics, Inc. | Oxysterol compounds |
| WO2012024581A2 (en) | 2010-08-20 | 2012-02-23 | Fate Therapeutics, Inc. | Oxysterol compounds |
| JP6262723B2 (ja) | 2012-05-07 | 2018-01-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | オキシステロールアナログｏｘｙ１３３は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する |
| EP2847205A4 (en) | 2012-05-07 | 2016-01-20 | Univ California | NOVEL OXYSTEROL ANALOGUE OXY149 FOR THE INDUCTION OF OSTEOGENESIS AND HEDGEHOG SIGNAL PATH AND THE INHIBITION OF ADIPOGENESIS |
| AU2014259672A1 (en) | 2013-05-02 | 2015-12-03 | The Regents Of The University Of California | Bone-selective osteogenic oxysterol-bone targeting agents |
| JP6530056B2 (ja) | 2014-05-02 | 2019-06-12 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア | 骨選択的骨形成オキシステロールビスホスホネート類似体 |
-
2013
- 2013-03-15 JP JP2015511471A patent/JP6262723B2/ja active Active
- 2013-03-15 AU AU2013260059A patent/AU2013260059B2/en active Active
- 2013-03-15 EP EP13788310.4A patent/EP2847206A4/en not_active Ceased
- 2013-03-15 WO PCT/US2013/032693 patent/WO2013169399A1/en not_active Ceased
- 2013-03-15 CN CN201380033045.2A patent/CN104395331B/zh active Active
- 2013-03-15 CA CA2872751A patent/CA2872751A1/en not_active Abandoned
- 2013-03-15 US US14/399,121 patent/US9717742B2/en active Active
- 2013-03-15 RU RU2014149164A patent/RU2632191C2/ru active
- 2013-03-15 KR KR1020147033925A patent/KR20150013232A/ko not_active Ceased
-
2014
- 2014-11-19 IN IN9805DEN2014 patent/IN2014DN09805A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015518493A5 (enExample) | ||
| JP2015517493A5 (enExample) | ||
| RU2014149164A (ru) | Аналог оксистерола oxy133 индуцирует остеогенез и сигнальный путь hedgehog и ингибирует липогенез | |
| Pilmane et al. | Strontium and strontium ranelate: Historical review of some of their functions | |
| Yuan et al. | The roles of exercise in bone remodeling and in prevention and treatment of osteoporosis | |
| RU2014149153A (ru) | Новый аналог оксистерола, oxy149, индуцирует остеогенез и сигнальный путь hedgehog и ингибирует липогенез | |
| Rutten et al. | Low-intensity pulsed ultrasound increases bone volume, osteoid thickness and mineral apposition rate in the area of fracture healing in patients with a delayed union of the osteotomized fibula | |
| Jimi et al. | The current and future therapies of bone regeneration to repair bone defects | |
| Gao et al. | The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats | |
| CA2643732A1 (en) | Oxysterol compounds and the hedgehog pathway | |
| Zhang et al. | Moderate-intensity 4 mT static magnetic fields prevent bone architectural deterioration and strength reduction by stimulating bone formation in streptozotocin-treated diabetic rats | |
| Yang et al. | Puerarin stimulates osteogenic differentiation and bone formation through the ERK1/2 and p38-MAPK signaling pathways | |
| Sun et al. | The effect of Gu-Sui-Bu (Drynaria fortunei J. Sm) on bone cell activities | |
| Tao et al. | Silibinin can promote bone regeneration of selenium hydrogel by reducing the oxidative stress pathway in ovariectomized rats | |
| Zhu et al. | Lactate mediates the bone anabolic effect of high-intensity interval training by inducing osteoblast differentiation | |
| Li et al. | Isoquercitrin, a flavonoid glucoside, exerts a positive effect on osteogenesis in vitro and in vivo | |
| Bradaschia-Correa et al. | Ecto-5′-nucleotidase (CD73) regulates bone formation and remodeling during intramembranous bone repair in aging mice | |
| Sritharan et al. | The synergistic effects of IL-6/IL-17A promote osteogenic differentiation by improving OPG/RANKL ratio and adhesion of MC3T3-E1 cells on hydroxyapatite | |
| Yin et al. | Shockwaves enhance the osteogenetic gene expression in marrow stromal cells from hips with osteonecrosis | |
| Choi et al. | Betulinic acid synergically enhances BMP2-induced bone formation via stimulating Smad 1/5/8 and p38 pathways | |
| Liu et al. | Coadministration of puerarin (low dose) and zinc attenuates bone loss and suppresses bone marrow adiposity in ovariectomized rats | |
| Jiang et al. | The effects of hypoxia-inducible factor (HIF)-1α protein on bone regeneration during distraction osteogenesis: an animal study | |
| Wang et al. | Effects of electroacupuncture at GB points on markers of osteoporosis and bodyweight in ovariectomised rats | |
| Li et al. | Matrine enhances osteogenic differentiation of bone marrow-derived mesenchymal stem cells and promotes bone regeneration in rapid maxillary expansion | |
| ES2701675T3 (es) | Irisina para el cuidado y la prevención de la osteoporosis |